ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial
- PMID: 21714923
- PMCID: PMC3146919
- DOI: 10.1186/1471-2350-12-89
ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in Non-Hispanic White Americans from the Look AHEAD Clinical Trial
Abstract
Background: Elevated triglyceride levels are a risk factor for cardiovascular disease. Angiopoietin-like protein 4 (Angptl4) is a metabolic factor that raises plasma triglyceride levels by inhibiting lipoprotein lipase (LPL). In non-diabetic individuals, the ANGPTL4 coding variant E40K has been associated with lower plasma triglyceride levels while the T266M variant has been associated with more modest effects on triglyceride metabolism. The objective of this study was to determine whether ANGPTL4 E40K and T266M are associated with triglyceride levels in the setting of obesity and T2D, and whether modification of triglyceride levels by these genetic variants is altered by a lifestyle intervention designed to treat T2D.
Methods: The association of ANGPTL4 E40K and T266M with fasting triglyceride levels was investigated in 2,601 participants from the Look AHEAD Clinical Trial, all of whom had T2D and were at least overweight. Further, we tested for an interaction between genotype and treatment effects on triglyceride levels.
Results: Among non-Hispanic White Look AHEAD participants, ANGPTL4 K40 carriers had mean triglyceride levels of 1.61 ± 0.62 mmol/L, 0.33 mmol/L lower than E40 homozygotes (p = 0.001). Individuals homozygous for the minor M266 allele (MAF 30%) had triglyceride levels of 1.75 ± 0.58 mmol/L, 0.24 mmol/L lower than T266 homozygotes (p = 0.002). The association of the M266 with triglycerides remained significant even after removing K40 carriers from the analysis (p = 0.002). There was no interaction between the weight loss intervention and genotype on triglyceride levels.
Conclusions: This is the first study to demonstrate that the ANGPTL4 E40K and T266M variants are associated with lower triglyceride levels in the setting of T2D. In addition, our findings demonstrate that ANGPTL4 genotype status does not alter triglyceride response to a lifestyle intervention in the Look AHEAD study.
Figures

Similar articles
-
ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels and predicts cardiovascular disease risk in Type 2 diabetic Tunisian population.Lipids Health Dis. 2016 Mar 23;15:63. doi: 10.1186/s12944-016-0231-6. Lipids Health Dis. 2016. PMID: 27004807 Free PMC article.
-
ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk.Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2319-25. doi: 10.1161/ATVBAHA.108.176917. Epub 2008 Oct 30. Arterioscler Thromb Vasc Biol. 2008. PMID: 18974381
-
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.N Engl J Med. 2016 Mar 24;374(12):1123-33. doi: 10.1056/NEJMoa1510926. Epub 2016 Mar 2. N Engl J Med. 2016. PMID: 26933753 Free PMC article.
-
Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events.Curr Opin Lipidol. 2010 Feb;21(1):70-5. doi: 10.1097/MOL.0b013e328333269e. Curr Opin Lipidol. 2010. PMID: 19851103 Review.
-
Regulation of triglyceride metabolism by Angiopoietin-like proteins.Biochim Biophys Acta. 2012 May;1821(5):782-9. doi: 10.1016/j.bbalip.2011.10.010. Epub 2011 Oct 25. Biochim Biophys Acta. 2012. PMID: 22063269 Review.
Cited by
-
Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease.Sci Rep. 2018 Apr 30;8(1):6752. doi: 10.1038/s41598-018-25237-7. Sci Rep. 2018. PMID: 29713054 Free PMC article.
-
Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.J Lipid Res. 2020 Aug;61(8):1203-1220. doi: 10.1194/jlr.RA120000781. Epub 2020 Jun 2. J Lipid Res. 2020. PMID: 32487544 Free PMC article.
-
Functional analysis of variance for association studies.PLoS One. 2014 Sep 22;9(9):e105074. doi: 10.1371/journal.pone.0105074. eCollection 2014. PLoS One. 2014. PMID: 25244256 Free PMC article.
-
Angiopoietin-Like Protein 4 May Be an Interplay Between Serum Uric Acid and Triglyceride-Rich Lipoprotein Cholesterol.Front Cardiovasc Med. 2022 May 31;9:863687. doi: 10.3389/fcvm.2022.863687. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35711366 Free PMC article.
-
Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generation sequencing.PLoS One. 2017 Aug 24;12(8):e0182828. doi: 10.1371/journal.pone.0182828. eCollection 2017. PLoS One. 2017. PMID: 28837672 Free PMC article.
References
-
- Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458. doi: 10.1161/CIRCULATIONAHA.106.637793. - DOI - PubMed
-
- Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, Woodward M. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110(17):2678–2686. - PubMed
-
- Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K. et al.Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383. - PMC - PubMed
-
- Tirosh A, Rudich A, Shochat T, Tekes-Manova D, Israeli E, Henkin Y, Kochba I, Shai I. Changes in triglyceride levels and risk for coronary heart disease in young men. Ann Intern Med. 2007;147(6):377–385. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources